Clinical Trials Logo

Lymphoma, B-cell clinical trials

View clinical trials related to Lymphoma, B-cell.

Filter by:

NCT ID: NCT05348213 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma

R-ICE+X
Start date: May 16, 2022
Phase: Phase 2
Study type: Interventional

A single-center, open, single-arm clinical study of the efficacy and safety of a novel targeted agent in combination with R-ICE in the treatment of relapsed and refractory diffuse Large B-cell lymphoma.

NCT ID: NCT05338931 Recruiting - Clinical trials for B-cell Non Hodgkin Lymphoma

Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Start date: March 15, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL.

NCT ID: NCT05335018 Recruiting - Clinical trials for Relapsed/Refractory Diffuse Large B Cell Lymphoma

GPL in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Start date: May 30, 2022
Phase: Phase 2
Study type: Interventional

Prospective, open-ended, single-arm, multicenter Phase II clinical trial. To evaluate the efficacy of Glofitamab, Poseltinib, and Lenalidomide combination therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

NCT ID: NCT05326243 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma

Start date: May 31, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multiple center, non-randomized, open-label, phase 1/2 study. The primary objective of Phase 1 is to evaluate the safety of PL001 and find the recommended Phase 2 dose (RP2D). The objective of Phase 2 is to evaluate the safety and efficacy of CD19 CAR-T(known as PL001).

NCT ID: NCT05322330 Recruiting - Clinical trials for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

Start date: February 10, 2022
Phase: Phase 2
Study type: Interventional

Aim of this study will evaluate the Efficacy and Safety of XPO-1 inhibitors in combination with CAR-T cells in relapsed refractory B-cell non-Hodgkin's lymphoma

NCT ID: NCT05318963 Recruiting - Clinical trials for B-cell Lymphoma Refractory

Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma

Start date: March 14, 2022
Phase: Phase 1
Study type: Interventional

A phase I, open-label clinical study to evaluate the safety, tolerability, and efficacy of LCAR-AIO, a triple-targeted cell preparation targeting CD19/CD20/CD22, in patients with relapsed/refractory B-cell lymphoma.

NCT ID: NCT05312801 Recruiting - Clinical trials for Lymphoma, Non-Hodgkin Lymphoma, B-Cell

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma

Start date: November 21, 2023
Phase: Phase 1
Study type: Interventional

Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory lymphoma, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractory lymphoma, even after relapse following cluster of differentiation antigen 19 (CD19) targeting CAR-T treatment. This phase 1 study will evaluate safe dose and provide initial signal of the activity of BAFF CAR-T cells against relapsed non-Hodgkin lymphoma using a single lymphodepletion regimen and using a BAFF CAR-T cell manufacturing process.

NCT ID: NCT05312476 Recruiting - Clinical trials for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma

Start date: February 10, 2022
Phase: Phase 2
Study type: Interventional

Aim of this study will evaluate the safety, tolerability and preliminary efficacy of chimeric antigen receptor T cells (CAR-T) targeting Igβ targets in patients with Igβ-positive refractory relapsed non-Hodgkin's lymphoma.

NCT ID: NCT05290337 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

ZR-CHOP in DLBCL With Specific Gene Abnormality

Start date: January 4, 2022
Phase: Phase 2
Study type: Interventional

This is a phase 2, single center clinical trial. to evaluating the efficacy and safety of Zanubrutinib in combination with R-CHOP in newly diagnosed diffuse large B-cell lymphoma with specific gene abnormality.

NCT ID: NCT05290090 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL

Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

As the most common subtype of lymphoma, diffuse large B-cell lymphoma (DLBCL) is an aggressive but potentially curable malignancy. The poor prognosis of elderly DLBCL patients may be related to the biological behavior of the disease, more comorbidities, poor performance status, and inability to tolerate standard-intensity immunochemotherapy. The investigators plan to use ZR2 regimen(rituximab, lenalidomide and zanubrutinib) for 2 cycles followed by immunochemotherapy for up to 4 cycles in elderly newly diagnosed DLBCL patients.